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Abstract
Background: Acute Lymphoblastic Leukaemia (ALL) is the most common cancer in children. Over the past four
decades, research has advanced the treatment of this cancer from a less than 60% chance of survival to over 85%
today. The causal molecular mechanisms remain unclear. Here, we performed sequencing-based genomic DNA
methylation profiling of eight paediatric ALL patients using archived bone marrow smear microscope slides.
Findings: SOLiD™ sequencing data was collected from Methyl-Binding Domain (MBD) enriched fractions of genomic
DNA. The primary tumour and remission bone marrow sample was analysed from eight patients. Four patients
relapsed and the relapsed tumour was analysed. Input and MBD-enriched DNA from each sample was sequenced,
aligned to the hg19 reference genome and analysed for enrichment peaks using MACS (Model-based Analysis for
ChIP-Seq) and HOMER (Hypergeometric Optimization of Motif EnRichment). In total, 3.67 gigabases (Gb) were
sequenced, 2.74 Gb were aligned to the reference genome (average 74.66% alignment efficiency). This dataset
enables the interrogation of differential DNA methylation associated with paediatric ALL. Preliminary results reveal
concordant regions of enrichment indicative of a DNA methylation signature.
Conclusion: Our dataset represents one of the first SOLiD™MBD-Seq studies performed on paediatric ALL and is the
first to utilise archival bone marrow smears. Differential DNA methylation between cancer and equivalent disease-free
tissue can be identified and correlated with existing and published genomic studies. Given the rarity of paediatric
haematopoietic malignancies, relative to adult counterparts, our demonstration of the utility of archived bone
marrow smear samples to high-throughput methylation sequencing approaches offers tremendous potential to
explore the role of DNA methylation in the aetiology of cancer.
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Data description
This project was approved by the Royal Children’s Hos-
pital Human Research Ethics Committee (RCH HREC#
29140C). We have performed Methyl-Binding Domain
protein 2 (MBD2) enrichment and isolated fractions of
*Correspondence: nwon@unimelb.edu.au
1Cancer and Disease Epigenetics Research Group, Murdoch Childrens
Research Institute, Royal Children’s Hospital, Flemington Road, 3052 Parkville,
Victoria, Australia
2Department of Paediatrics, The University of Melbourne, Royal Children’s
Hospital, Flemington Road, 3052, Parkville, Victoria, Australia
Full list of author information is available at the end of the article
DNA from 40 individuals for sequencing on the Sequenc-
ing by Oligonucleotide Ligation and Detection (SOLiD™)
sequencing platform (SOLiD™MBD-Seq, Life Technolo-
gies, Carlsbad, USA). MBD2 has been shown to bind to
double-stranded methylated DNA molecules and used to
interrogate the human methylome [1]. By comparing the
enriched fraction to the "input" total genomic DNA frac-
tion, genomic regions of DNAmethylation can be inferred
after sequencing both fractions. The samples analysed are
comprised of the following: three model cell lines, JWL
(an in-house non-leukaemic cell line [2]), CEM-CCRF
(childhood T-cell acute lymphoblastic leukaemia [ALL]
© 2015 Wong et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Table 1 Samples analysed in this study and sequencingmetrics
Sequencing chemistry Sample TotalTags UniqueTags Alignment efficiency
SOLiD v3 JWL(1ug)-E 82,825,332 25,878,330 31.24%
JWL(5ug)-E 41,496,636 16,004,583 38.57%
CEM-CCRF-E 70,843,054 23,576,689 33.28%
K562-E 67,818,656 19,407,273 28.62%
Leuk316-E 86,478,570 29,043,378 33.58%
Lap316-E 74,223,311 19,719,258 26.57%
Rem316-E 77,702,366 23,783,043 30.61%
NB-Leuk 84,461,471 44,789,628 53.03%
SOLiD v4 bm9_cd19-E 38,269,892 22,810,020 59.60%
bm9_cd19-I 37,784,067 34,877,526 92.31%
bm9_cd33-E 10,416,743 6,266,457 60.16%
bm9_cd33-I 42,759,158 39,428,521 92.21%
bm9_cd34-E 51,318,758 29,465,956 57.42%
bm9_cd34-I 46,036,938 42,428,715 92.16%
bm9_cd45-E 12,914,609 9,361,359 72.49%
bm9_cd45-I 33,483,409 31,189,190 93.15%
bm10_cd19-E 45,846,788 23,820,768 51.96%
bm10_cd19-I 42,916,292 39,433,442 91.88%
bm10_cd33-E 18,881,635 12,678,559 67.15%
bm10_cd33-I 36,392,688 33,622,173 92.39%
bm10_cd34-E 1,455,904 976,835 67.09%
bm10_cd34-I 43,740,869 38,954,344 89.06%
bm10_cd45-E 47,832,605 31,267,133 65.37%
bm10_cd45-I 56,272,359 51,839,725 92.12%
Lap197-E 23,613,069 17,771,922 75.26%
Lap197-I 40,839,842 37,160,823 90.99%
Lap316-E 22,312,029 18,406,671 82.50%
Lap316-I 65,985,869 59,587,559 90.30%
Lap362-E 26,103,269 18,291,098 70.07%
Lap362-I 43,663,529 39,464,174 90.38%
Lap367-E 30,436,848 22,390,188 73.56%
Lap367-I 61,426,571 55,393,215 90.18%
Leu135-E 28,518,319 22,184,998 77.79%
Leu135-I 66,384,953 59,496,167 89.62%
Leu197-E 40,781,905 21,042,700 51.60%
Leu197-I 100,952,576 88,986,493 88.15%
Leu292-E 37,383,290 27,245,488 72.88%
Leu292-I 81,946,813 73,469,308 89.65%
Leu316-E 19,691,035 15,476,011 78.59%
Leu316-I 49,443,957 44,399,793 89.80%
Leu362-E 26,155,137 19,508,962 74.59%
Leu362-I 52,718,699 47,588,023 90.27%
Leu367-E 30,436,848 22,390,188 73.56%
Wong et al. GigaScience  (2015) 4:11 Page 3 of 6
Table 1 Samples analysed in this study and sequencingmetrics (Continued)
Sequencing chemistry Sample TotalTags UniqueTags Alignment efficiency
Leu367-I 61,426,571 55,393,215 90.18%
Leu378-E 37,963,480 25,159,304 66.27%
Leu378-I 63,946,621 57,452,718 89.84%
Leu386-E 34,541,207 26,730,838 77.39%
Leu386-I 85,783,795 76,829,088 89.56%
pbsc1_cd19-E 28,300,798 17,236,825 60.91%
pbsc1_cd19-I 42,994,203 39,873,845 92.74%
pbsc1_cd33-E 28,441,237 17,222,149 60.55%
pbsc1_cd33-I 41,190,719 38,084,036 92.46%
pbsc1_cd34-E 30,595,326 18,228,854 59.58%
pbsc1_cd34-I 40,582,296 37,607,618 92.67%
pbsc1_cd45-E 21,807,673 11,901,508 54.57%
pbsc1_cd45-I 44,739,461 41,071,013 91.80%
pbsc2_cd19-E 35,937,656 20,893,976 58.14%
pbsc2_cd19-I 39,678,926 36,769,939 92.67%
pbsc2_cd33-E 35,344,009 22,387,891 63.34%
pbsc2_cd33-I 32,507,100 30,204,900 92.92%
pbsc2_cd34-E 25,845,401 13,736,296 53.15%
pbsc2_cd34-I 48,706,315 44,827,413 92.04%
pbsc2_cd45-E 32,212,432 21,627,452 67.14%
pbsc2_cd45-I 47,235,290 43,581,366 92.26%
Rem135-E 36,998,278 24,794,225 67.01%
Rem135-I 123,775,359 108,611,090 87.75%
Rem197-E 32,669,979 20,692,190 63.34%
Rem197-I 72,248,569 64,234,959 88.91%
Rem292-E 40,308,561 29,524,878 73.25%
Rem292-I 56,187,553 50,646,668 90.14%
Rem316-E 29,052,098 23,634,221 81.35%
Rem316-I 60,566,396 54,693,711 90.30%
Rem362-E 30,583,568 24,759,911 80.96%
Rem362-I 59,138,768 53,532,111 90.52%
Rem367-E 27,854,950 20,285,938 72.83%
Rem367-I 53,616,042 48,017,388 89.56%
Rem378-E 19,428,372 14,820,513 76.28%
Rem378-I 58,333,370 51,624,942 88.50%
Rem386-E 26,909,681 19,355,786 71.93%
Rem386-I 83,504,227 74,547,836 89.27%
Total 3,671,922,955 2,741,473,297 74.66%
cell line) and K562 (adult chronic myelogenous leukaemia
cell line). From two non-leukaemic individuals (pbsc1 and
pbsc2), peripheral blood mononuclear cells were sampled
and four haematopoietic cell populations (CD34-positive,
CD19-positive, CD33-positive and CD45-positive) were
isolated for SOLiD™MBD-Seq analysis. From another two
non-leukaemic individuals (bm9 and bm10), the same
haematopoietic cell populations were isolated from bone
marrow. Eight cases of childhood ALL were analysed with
the identifiers 135, 197, 292, 316, 362, 367, 378 and 386 at
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diagnosis (leuk) and 28 days post induction chemotherapy
(rem). A third set of samples was taken at relapse (lap) for
cases 197, 316, 362 and 367 (Table 1).
Genomic DNA from archived bone marrow smear
microscope slides from ALL patients, cells and cell
lines were extracted as previously described [3] and
used for the enrichment of CpG methylation with the
MethylMiner™ Methylated DNA enrichment kit (Life
Technologies) according to the manufacturer’s protocols.
The fragmented input genomic DNA (I) and enriched E5
fraction (E) were isolated from each sample for library
preparation and sequencing using SOLiD™ v3 and v4
chemistry according to the manufacturer’s protocols (Life
Technologies).
Single and paired-end SOLiD™ sequencing reads were
aligned using LifeScope™ Genomic Analysis Suite (Life
Technologies) with default parameters against the hg19
reference genome. Alignment efficiency (the ratio of
Figure 1 Venn diagrams summarising peak region overlaps between samples analysed in this study. Overlapping peak regions are shown
after MACS peak analysis. (A) Peaks on chromosome 21 from three non-leukaemic individuals where CD19 cells were positively selected using FACS.
A high degree of overlapping peaks were observed. (B) Peaks from matching leukaemic and remission samples from individual 135. Although there
are some overlapping peaks (183), there are a substantial number of distinct peaks in each sample. (C) The extent of overlapping peaks between 3
leukaemic samples. (D) The extent of overlapping peaks between 3 remission samples.
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uniquely aligned reads to total sequenced reads for each
sample) ranged from 26.57% to 93.15% across all samples
in this study (Table 1).
Alignments were then processed using MACS (Model-
based Analysis for ChIP-Seq) [4] and HOMER (Hyper-
geometric Optimization of Motif EnRichment) [5,6] to
identify enrichment peaks.
This study is unique in a number of ways. This is the
first sequencing-based DNA methylation profiling study
in childhood ALL using archived bone marrow samples
of similar quality to formalin-fixed paraffin-embedded
(FFPE) tissue samples [7]. We have selected samples that
have been interrogated using an orthogonal platform, the
Illumina Infinium Human Methylation 450K BeadArray
[3,8], and included replicate samples to assess the repro-
ducibility of SOLiD™MBD-Seq and to identify regions
of differential DNA methylation of interest to childhood
ALL.
We performed replicate DNA methylation enrichment
analysis using the JWL cell line with 1μg and 5μg of start-
ing genomic DNA to determine if 1μg of starting material
was sufficient for DNAmethylation enrichment. This was
less than the recommended quantity but a typical amount
obtainable from our primary patient samples.
We isolated four haematopoietic cell populations
(CD34, CD19, CD33, CD45) at major stages of develop-
ment corresponding to the arrested stages of development
in paediatric leukaemia. This was achieved by positive
selection using fluorescent-labelled antibodies and Flu-
orescent Activated Cell Sorting (FACS) from four indi-
viduals. This would enable us to track changes in DNA
methylation between cell lineages and contrast them with
leukaemic cells. After MACS enrichment peak analy-
sis, a large proportion of peaks were common between
the CD19 cells from three individuals, confirming the
premise of tissue-specific DNA methylation profiles in
haematopoietic cells (Figure 1A).
When comparing DNA methylation enrichment peaks
between leukaemic and remission samples (tumour ver-
sus normal) from the same individual, distinct enrichment
peaks are seen; these are likely to correlate to disease state
(Figure 1B). The number of overlapping peaks between
leukaemic and remission samples were fewer compared to
the haematopoietic cell analyses (Figure 1C and 1D) and
could be indicative of the difference in sample qualities.
For each of the samples analysed in this study, we have
generated track hubs that can be uploaded and visu-
alised on the UCSC Genome Browser. This permits the
immediate visualisation of regions of differential DNA
methylation with potential biological significance. More-
over, we have performed Infinium analysis on these sam-
ples, and visualisation using the Genome Browser permits
direct comparison to other publicly available data such
as The Cancer Genome Atlas (TCGA) [9] and TARGET
(Therapeutically Applicable Research to Generate Effec-
tive Treatments) [10]. This also permits further analysis
and comparison to publicly available data using the Galaxy
[11,12] and Cistrome [13] web servers.
In summary, our data represent one of the first DNA
methylation enrichment analyses using SOLiD™MBD-Seq
on archival bone marrow smears from children diagnosed
with ALL. Such specimens are readily available in most
pathology laboratories across the world and are amenable
to genomic-scale analysis, as we have demonstrated here.
These data should prove valuable for other DNA methy-
lation studies in childhood ALL in haematopoeitic cell
development.
Availability of supporting data
Supporting data is available from the GigaScience
Database, GigaDB [14] and at NCBI under BioProject
PRJNA272864.
Data file details
• SRA Files included BioProject PRJNA272864
• MACS and HOMER output files of peaks and peak
locations
• Track Hubs for UCSC Genome Browser
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